Abbott Laboratories $ABT Holdings Boosted by Alliancebernstein L.P.

Alliancebernstein L.P. raised its position in shares of Abbott Laboratories (NYSE:ABT) by 51.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,525,906 shares of the healthcare product maker’s stock after purchasing an additional 1,865,250 shares during the quarter. Alliancebernstein L.P. owned 0.32% of Abbott Laboratories worth $740,140,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Cloud Capital Management LLC acquired a new position in Abbott Laboratories during the third quarter valued at $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories during the 3rd quarter worth about $31,000. Anfield Capital Management LLC grew its stake in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares in the last quarter. Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories in the 2nd quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were bought at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the purchase, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 3,055 shares of company stock worth $353,097 in the last ninety days. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

NYSE:ABT opened at $107.99 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.06. The company has a fifty day moving average price of $114.58 and a 200 day moving average price of $123.86. The stock has a market cap of $187.66 billion, a P/E ratio of 29.03, a PEG ratio of 1.72 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the previous year, the firm posted $1.34 EPS. The business’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is 67.74%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ABT shares. Leerink Partners dropped their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. BTIG Research lowered their target price on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Daiwa Securities Group dropped their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Barclays reduced their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Finally, Citigroup lowered their price target on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.